Company Encyclopedia
View More
name
Turn Therapeutics
TTRX.US
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025.
4.599 T
TTRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CFO Chaudhary Buys 2,500 ($8.8K) Of Turn Therapeutics Inc [TTRX]

    Chaudhary Zuraiz Chief Financial Officer of Turn Therapeutics Inc [TTRX] filed a Form 4 on December 12, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/12/25TransactionPurchaseShares2,500Price$3.50Value$8,750Ending Holdings: 12,500 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    TTRX
    +6.23%
    Reuters·
    US
    TTRX
    +6.23%

    Turn Therapeutics (NASDAQ:TTRX) Director Purchases $33,945.92 in Stock

    Turn Therapeutics Director Arthur Golden purchased 9,868 shares, increasing his ownership by 19.45%. The transaction, valued at $33,945.92, was disclosed in an SEC filing. The stock price decreased by $0.20 to $3.30, with a trading volume of 82,657 shares. Turn Therapeutics reported a quarterly EPS of ($0.07).

    Market Beat·
    US
    TTRX
    +6.23%
    Market Beat·
    US
    TTRX
    +6.23%

    Director Arthur F. Golden Acquires Common Shares of Turn Therapeutics Inc

    Arthur F. Golden, Director at Turn Therapeutics Inc., has acquired common shares of the company. This information was disclosed through a filing on the EDGAR system by the U.S. Securities and Exchange Commission. The news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    TTRX
    +6.23%
    Reuters·
    US
    TTRX
    +6.23%

    Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares

    Arthur F. Golden, a director at Turn Therapeutics Inc., has acquired common shares of the company. This information was originally published by Turn Therapeutics Inc. via the EDGAR system of the U.S. Securities and Exchange Commission.

    Reuters·
    US
    TTRX
    +6.23%
    Reuters·
    US
    TTRX
    +6.23%

    CFO Chaudhary Buys 2,450 ($7.1K) Of Turn Therapeutics Inc [TTRX]

    Chaudhary Zuraiz Chief Financial Officer of Turn Therapeutics Inc [TTRX] filed a Form 4 on November 21, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/20/25-11/21/25TransactionPurchaseShares2,450Price$2.89Value$7,075Ending Holdings: 10,000 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    TTRX
    +6.23%
    Reuters·
    US
    TTRX
    +6.23%
    © 2025 Longbridge｜Disclaimer